GGrantIndex
← Leaderboards

Thomas E. Lloyd

Johns Hopkins University

$7,156,262
Attributed
$11,666,017
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY200825
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,666,017 · 6

By mechanism

R01$10,682,046 · 4
K08$878,175 · 1
UE5$105,796 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Neurons

Research focus

NeuronsCellsPathologyAlzheimer&AposNeurodegenerative DisordersPathogenesisInsightHuman DiseaseDrosophila GenusProteinsFunctional DisorderAdultMouse ModelAnimalsAnimal ModelTraffickingImpairmentExhibitsEventSignal TransductionGeneticTissuesIn VivoMediating

Grant awards (26)

Baylor Research Education Program in Clinical Neurosciences$105,796
UE5 · FY2025 · NS
Neuronal cell-cycle re-entry and neurodegeneration$659,691
R01 · FY2024 · AG
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$448,276
R01 · FY2024 · AR
Neuronal cell-cycle re-entry and neurodegeneration$659,691
R01 · FY2023 · AG
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$462,140
R01 · FY2023 · AR · contact PI
Neuronal cell-cycle re-entry and neurodegeneration$659,691
R01 · FY2022 · AG
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$457,518
R01 · FY2022 · AR · contact PI
Neuronal cell-cycle re-entry and neurodegeneration$656,416
R01 · FY2021 · AG
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$448,277
R01 · FY2021 · AR · contact PI
Neuronal cell-cycle re-entry and neurodegeneration$665,765
R01 · FY2020 · AG
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$653,024
R01 · FY2020 · NS
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.$413,993
R01 · FY2020 · AR · contact PI
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$653,024
R01 · FY2019 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$650,895
R01 · FY2018 · NS
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$648,990
R01 · FY2017 · NS
Dynactin function in axons, synapses, and neurodegenerative disease$354,375
R01 · FY2017 · NS · contact PI
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD$776,323
R01 · FY2016 · NS
Dynactin function in axons, synapses, and neurodegenerative disease$354,375
R01 · FY2016 · NS · contact PI
Dynactin function in axons, synapses, and neurodegenerative disease$354,375
R01 · FY2015 · NS · contact PI
Dynactin function in axons, synapses, and neurodegenerative disease$350,832
R01 · FY2014 · NS · contact PI
Dynactin function in axons, synapses, and neurodegenerative disease$354,375
R01 · FY2013 · NS · contact PI
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.$175,635
K08 · FY2012 · NS · contact PI
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.$175,635
K08 · FY2011 · NS · contact PI
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.$175,635
K08 · FY2010 · NS · contact PI
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.$175,635
K08 · FY2009 · NS · contact PI
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.$175,635
K08 · FY2008 · NS · contact PI